J Cancer Policy
September 2024
This report provides a concise overview of how Georgia has integrated the principles of the European Code Against Cancer (ECAC) into its national cancer strategies. Through a structured exploration, we highlight Georgia's commitment to cancer prevention, while addressing the challenges and opportunities encountered.
View Article and Find Full Text PDFPurpose: This study aims to examine the availability and comprehensiveness of policies pertaining to colorectal cancer (CRC) in Central, Eastern European and South Caucasus countries, as it is a major public health concern in these regions and the second most common cause of cancer deaths among women.
Design/methodology/approach: We performed a scoping review using the Arksey and O'Malley methodology, searching for publicly available policy documents from 18 countries. We described the prevention methods and activities in each country based on the World Health Organization guidelines for CRC screening.
Digestive organ cancer, also known as gastrointestinal (GI) cancer, refers to cancer that occurs in the digestive tract. In this population-based registry study, we aimed to investigate the incidence of GI in Georgia and to identify any patterns in the occurrence of different types of this disease. The study included all cases of GI cancer that were diagnosed in Georgia in 2021.
View Article and Find Full Text PDFIntroduction: CRC is one of the most common and serious public health problem. In Georgia, it ranks among the top five most fatal cancers for both men and women. This study aimed to utilize cancer registry data to evaluate the incidence and stage distribution of CRC in Georgia.
View Article and Find Full Text PDFInt J Tuberc Lung Dis
September 2009
Background: Tuberculosis (TB) control in Georgia follows the World Health Organization-recommended DOTS strategy, and has reached global TB control targets in the treatment of susceptible TB; however, the management of drug-resistant forms of TB still represents a serious problem. A countrywide drug resistance survey (DRS) found that the prevalence of multidrug-resistant TB (MDR-TB) was respectively 6.8% and 27.
View Article and Find Full Text PDF